• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Poland·Healthcare·SLV.WA
Share

Selvita S.A. Stocks

PLN 18Last Updated 13.11.2026

Issuer Rating

3/7
Performance

Average

Risk

Considerable

Recommendation

Sell

Market Cap

PLN 76.11M

PLN 18
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Favourable analyst view

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Selvita S.A., a contract research organization (CRO), provides its services across Poland, throughout Europe, in the United States, and to global clients. The company is structured around two main divisions: its core Contract Research Organization (CRO) offerings and Bioinformatics. Within its drug discovery portfolio, Selvita delivers a comprehensive suite of services including assay development and screening, expertise in medicinal and synthetic chemistry, advanced computer-aided drug design leveraging artificial intelligence, structural biology, in vitro and in vivo pharmacology studies, ADME/DMPK assessments, and general analytical testing. Furthermore, Selvita extends its capabilities to pharmaceutical services, encompassing drug testing and bioanalytical analysis. These services cover development and optimization processes, validation and transfer, stability studies, rigorous quality control, and assistance with regulatory compliance. The organization also engages in diverse research and development activities, such as process research, bespoke laboratory-scale synthesis of New Chemical Entities (NCEs), industrial chemistry solutions, and the creation of isotopically labeled compounds. Support for the agrochemical industry is also part of their R&D offerings. Moreover, Selvita delivers specialized bio-data science and sophisticated software solutions tailored for data-centric organizations within the life science and healthcare sectors. Established in 2007, Selvita S.A. maintains its headquarters in Krakow, Poland.

Company Valuation

Slightly undervalued
5/7

From both historical and forecast perspectives, the stock is moderately underpriced compared to similar stocks. Specifically, the stock is 'expensive' on P/E, neutral on

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Favourable
6/7

The average target price of SLV.WA is 37.8 and suggests 110% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to inc

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

14.11.2026 17:01

What's New in Small-Cap Stocks: The Forbes Ranking, Oklo's Plans for Meta, and Ceco's Record

14.11.2026 13:01

Is There Life After Huang? The Rise of Anthropic, and the AI Rally in the Clouds

14.11.2026 04:56

Key Starship tests did not go as planned. SpaceX shares fell

14.11.2026 04:35

The S&P 500 posted its best week in six months. Barclays expects growth for the first time since March

14.11.2026 03:40

Huang still holds $135 billion worth of Nvidia stock. Why is this worrying investors?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026